Skip to content
DeepViews

Haemonetics Corporation (HAE) — 分析摘要

Haemonetics Corporation(HAE)的市值为5.54十亿美元,最近一年的营收同比增长了-2.0%。净利润率为7.3%。当前市盈率为57.5倍。

核心要点

  • 营收同比变化-2.0%
  • 净利润率7.3%
  • 市盈率57.5倍

与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,HAE的营收增长为-2.0%,市盈率为57.5倍。

[XNYS]

Haemonetics Corporation (HAE)

$121.72

前收盘价 2026-10-13 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$5537.90M
企业价值
$6488.68M
市盈率
57.5
股息率
0.00%
EV/EBITDA
24.0
公司简介
关于
关于 Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

行业

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

员工人数

3,009

总部

BOSTON, MA

Exchange

XNYS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
56
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$837.10M
总债务$1174.16M
债务权益比1.40
现金及等价物$223.38M

现金流

经营现金流$328.15M
自由现金流$291.22M
自由现金流率21.54%
P/FCF 比率19.02
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。